Our Blog
-
BioUtah Letter on Prioritizing Life Sciences Workers for Vaccine Distribution
December 3, 2020 Mr. Rich Lakin, MSPH, MPA Immunizations Director Utah Department of Health Bureau of Epidemiology PO…
-
ProLung Has a New Name, Gets $3.3 Million Private Placement and More…
ProLung, now IONIQ Sciences (IONIQ), has been on a roll! Last week, the company announced that they had fully…
-
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in…
-
Salt Lake City Angels Invests in Freyya
Salt Lake City Angels Invests in Freyya
-
Owlet Extends Global Reach with Launch of Medically-Certified Dream Sock™ to South Africa
The wearable baby monitor trusted by millions globally expands reach to three continents, including North America, Europe, and…
-
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment…
-
BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative
BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative
-
PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy
Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy
-
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of…
-
Halia Therapeutics Published in Journey of Drug Targeting
Halia Therapeutics Published in Journey of Drug Targeting
-
CancerVax Achieves Major Milestones and Files Foundational Patent Application
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform